Swiss National Bank
LYEL icon

Swiss National Bank’s Lyell Immunopharma LYEL Stock Holding History

Swiss National Bank’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12,370
Closed -$341K – 2461
2024
Q3 		$341K Hold
12,370
– – ﹤0.01% 2460
2024
Q2 		$359K Hold
12,370
– – ﹤0.01% 2445
2024
Q1 		$552K Hold
12,370
– – ﹤0.01% 2431
2023
Q4 		$480K Sell
12,370
-1,215
-9% -$43.8K ﹤0.01% 2481
2023
Q3 		$399K Hold
13,585
– – ﹤0.01% 2547
2023
Q2 		$864K Buy
+13,585
New +$752K ﹤0.01% 2371

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Swiss National Bank's LYEL Position: Q4 2024 in Review

Swiss National Bank sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 12,370 shares — an estimated $341K sold.

Swiss National Bank first reported a position in LYEL in Q2 2023 and held it in 6 quarters. The position peaked at $864K in Q2 2023. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Swiss National Bank reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Swiss National Bank sold 12,370 Lyell Immunopharma shares in Q4 2024, an estimated $341K.
  • Swiss National Bank first reported a position in Lyell Immunopharma in Q2 2023 and held it in 6 quarters.
  • Swiss National Bank's Lyell Immunopharma position peaked at $864K in Q2 2023.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Swiss National Bank's 13F filing for Q4 2024, filed 10 Feb 2025.